GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

Phase 3

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rosiglitazone

First Posted Date: 2007-01-29

Last Posted Date: 2017-05-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 862

Registration Number: NCT00428090

Locations: 🇬🇧
GSK Investigational Site, West of Scotland Science Park, Glasgow, United Kingdom

A Three-Part Study Of GSK580416 In Healthy Subjects

Phase 1

Completed

Conditions: Respiratory Tract Infection
Infections, Bacterial

First Posted Date: 2007-01-26

Last Posted Date: 2012-06-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 48

Registration Number: NCT00427141

Locations: 🇦🇺
GSK Investigational Site, Randwick, Sydney, New South Wales, Australia

To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia

Phase 2

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Drug: SB-649868
Drug: Placebo

First Posted Date: 2007-01-25

Last Posted Date: 2012-08-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 48

Registration Number: NCT00426816

Locations: 🇩🇪
GSK Investigational Site, Hamburg, Germany

Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)

Phase 3

Completed

Conditions: Infarction, Myocardial

Interventions: Drug: Abciximab
Drug: Eptifibatide

First Posted Date: 2007-01-25

Last Posted Date: 2012-11-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 429

Registration Number: NCT00426751

Locations: 🇩🇪
GSK Investigational Site, Homburg, Saarland, Germany

To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.

Phase 1

Completed

Conditions: Depressive Disorder and Anxiety Disorders

Interventions: Drug: metyrapone
Drug: alprazolam
Drug: placebo
Drug: GSK561679

First Posted Date: 2007-01-25

Last Posted Date: 2017-09-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT00426608

Locations: 🇬🇧
GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

Phase 3

Completed

Conditions: Infections, Papillomavirus

Interventions: Biological: Boostrix ® Polio
Biological: GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)

First Posted Date: 2007-01-24

Last Posted Date: 2018-07-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 751

Registration Number: NCT00426361

Locations: 🇪🇸
GSK Investigational Site, Sevilla, Spain

Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants

Phase 2

Completed

Conditions: Infections, Rotavirus

First Posted Date: 2007-01-23

Last Posted Date: 2016-09-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 405

Registration Number: NCT00425737

A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.

Phase 1

Completed

Conditions: Healthy Subjects

First Posted Date: 2007-01-19

Last Posted Date: 2010-10-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT00424697

Locations: 🇺🇸
GSK Investigational Site, La Jolla, California, United States

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

Phase 3

Completed

Conditions: Neoplasms, Head and Neck

Interventions: Radiation: Chemoradiation
Drug: Lapatinib
Other: Placebo

First Posted Date: 2007-01-19

Last Posted Date: 2014-07-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 688

Registration Number: NCT00424255

Locations: 🇬🇧
GSK Investigational Site, Sutton, United Kingdom

A Study of GSK1325760A in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Healthy Subjects

First Posted Date: 2007-01-18

Last Posted Date: 2017-01-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 32

Registration Number: NCT00424034

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy